NASDAQ
115.63USD
+3.53 (+3.15%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
7.9B
P/E
—
EPS
—
Beta
1.97
52W range
74.5-122.2
Day range
111.69–116.18
Open
113.98
Prev close
112.10
Volume
672.8K
Avg volume
869.6K
Dividend
0.00
IPO
2017-10-09
https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-viking-therapeutics-inc-to-contact-law-firm-302831251.html · 7/21/2026-0.80
https://www.globenewswire.com/news-release/2026/07/17/3328889/0/en/Kuehn-Law-Encourages-Investors-of-Rhythm-Pharmaceuticals-Inc-to-Contact-Law-Firm.html · 7/17/2026-0.80
https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-five9-inc-to-contact-law-firm-302817180.html · 7/2/2026-0.80
https://seekingalpha.com/article/4904256-rhythm-pharmaceuticals-inc-rytm-presents-at-bank-of-america-global-healthcare-conference-2026 · 5/14/2026+0.00
https://www.globenewswire.com/news-release/2026/04/03/3268007/0/en/Rhythm-Pharmaceuticals-Announces-Changes-to-Board-of-Directors.html · 4/3/2026
https://www.globenewswire.com/news-release/2026/03/19/3259502/0/en/Rhythm-Pharmaceuticals-Announces-FDA-Approval-of-IMCIVREE-setmelanotide-for-Patients-with-Acquired-Hypothalamic-Obesity.html · 3/19/2026+1.00
https://www.globenewswire.com/news-release/2026/03/16/3256684/0/en/Rhythm-Pharmaceuticals-Announces-Topline-Results-from-Phase-3-EMANATE-Trial.html · 3/16/2026-0.60
https://www.benzinga.com/analyst-stock-ratings/initiation/26/02/50728058/rhythm-pharmaceuticals-is-well-positioned-analyst-says-could-capture-big-share-of-rare-obesity-market · 2/19/2026+1.00
https://www.defenseworld.net/2025/12/20/assenagon-asset-management-s-a-sells-13870-shares-of-rhythm-pharmaceuticals-inc-rytm.html · 12/20/2025-0.20
https://seekingalpha.com/article/4852666-rhythm-pws-signal-ho-speed-bump-and-the-case-for-a-rare-obesity-blockbuster · 12/11/2025+0.60
https://www.benzinga.com/news/health-care/25/12/49343359/rhythm-pharma-strikes-chord-as-early-pws-trial-results-show-promise · 12/11/2025+1.00
https://www.fool.com/coverage/filings/2025/11/08/rythm-pharmaceuticals-rytm-chief-technical-officer-sells-9-748-shares-for-usd1-1-million/ · 11/8/2025-0.20
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
